Adolor Corporation’s Complete Response To Approvable Letter For Entereg(R) (Alvimopan) In POI Accepted For Review By FDA

EXTON & PHILADELPHIA, Pa.--(BUSINESS WIRE)--May 31, 2006--Adolor Corporation (Nasdaq: ADLR - News) and GlaxoSmithKline (NYSE: GSK - News) announced today that the Food and Drug Administration (FDA) has accepted as complete, Adolor's response to the July 2005 New Drug Application (NDA) approvable letter for Entereg for the management of post-operative ileus (POI). The FDA informed Adolor that the response is considered a class 2 resubmission with a user fee goal date of November 9, 2006.